Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Leuk Lymphoma. 2017 Jun 13;59(3):542–561. doi: 10.1080/10428194.2017.1337115

Figure 1. Application of “omics” technologies in preclinical research (bench) and clinical practice (bedside)Bench:

Figure 1.

The use of “omics” technologies in pre-clinical research has and will continue to facilitate the development of (1) better risk stratification systems, (2) biomarker discovery, (3) rational drug combinations to overcome resistance, and (4) novel targeted and immunotherapies for use in the diagnostic workup and treatment of patients with MM. Bedside: Although at present, “omics” technologies are not ready for immediate clinical use as diagnostic, prognostic, or response/relapse monitoring tools, it can be envisaged that simple, rapid, robust, portable, and cost-effective clinical diagnosis, prognosis, and disease monitoring systems could be available in near future, which would not only improve clinical decisions but also guide the design of more clinically pertinent, bench to bedside research. Bench to bedside research, Beside to bench research, Application of “omics” technologies, TAA: tumor-associated antigens, GEP: gene expression profiling